TY - JOUR
T1 - Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
AU - De Roock, Wendy
AU - Claes, Bart
AU - Bernasconi, David
AU - De Schutter, Jef
AU - Biesmans, Bart
AU - Fountzilas, George
AU - Kalogeras, Konstantine T
AU - Kotoula, Vassiliki
AU - Papamichael, Demetris
AU - Laurent-Puig, Pierre
AU - Penault-Llorca, Frédérique
AU - Rougier, Philippe
AU - Vincenzi, Bruno
AU - Santini, Daniele
AU - Tonini, Giuseppe
AU - Cappuzzo, Federico
AU - Frattini, Milo
AU - Molinari, Francesca
AU - Saletti, Piercarlo
AU - De Dosso, Sara
AU - Martini, Miriam
AU - Bardelli, Alberto
AU - Siena, Salvatore
AU - Sartore-Bianchi, Andrea
AU - Tabernero, Josep
AU - Macarulla, Teresa
AU - Di Fiore, Frédéric
AU - Gangloff, Alice Oden
AU - Ciardiello, Fortunato
AU - Pfeiffer, Per
AU - Qvortrup, Camilla
AU - Hansen, Tine Plato
AU - Van Cutsem, Eric
AU - Piessevaux, Hubert
AU - Lambrechts, Diether
AU - Delorenzi, Mauro
AU - Tejpar, Sabine
N1 - 2010 Elsevier Ltd. All rights reserved.
PY - 2010/8/1
Y1 - 2010/8/1
N2 - Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving cetuximab or panitumumab. However, most patients with KRAS wild-type tumours still do not respond. We studied the effect of other downstream mutations on the efficacy of cetuximab in, to our knowledge, the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era.
AB - Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving cetuximab or panitumumab. However, most patients with KRAS wild-type tumours still do not respond. We studied the effect of other downstream mutations on the efficacy of cetuximab in, to our knowledge, the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antibodies, Monoclonal
KW - Antineoplastic Agents
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Colorectal Neoplasms
KW - Drug Resistance, Neoplasm
KW - Female
KW - Genes, ras
KW - Humans
KW - Male
KW - Middle Aged
KW - Multivariate Analysis
KW - Mutation
KW - Phosphatidylinositol 3-Kinases
KW - Proportional Hazards Models
KW - Proto-Oncogene Proteins B-raf
KW - ROC Curve
KW - Retrospective Studies
KW - Survival Analysis
KW - Tumor Markers, Biological
U2 - 10.1016/S1470-2045(10)70130-3
DO - 10.1016/S1470-2045(10)70130-3
M3 - Journal article
C2 - 20619739
SN - 1470-2045
VL - 11
SP - 753
EP - 762
JO - Lancet Oncology
JF - Lancet Oncology
IS - 8
ER -